{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T18:15:43Z","timestamp":1781892943293,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["72074123"],"award-info":[{"award-number":["72074123"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s11096-025-01969-1","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T09:47:28Z","timestamp":1755596848000},"page":"1510-1519","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacovigilance analysis of metabolic and nutritional adverse reactions associated with entecavir and tenofovir using the FDA adverse event reporting system database"],"prefix":"10.1007","volume":"47","author":[{"given":"Haomin","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baolong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuying","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongting","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3951-8061","authenticated-orcid":false,"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"issue":"10161","key":"1969_CR1","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","volume":"392","author":"W Seto","year":"2018","unstructured":"Seto W, Lo Y, Pawlotsky J, et al. Chronic hepatitis B virus infection. Lancet. 2018;392(10161):2313\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(18)31865-8.","journal-title":"Lancet"},{"issue":"12","key":"1969_CR2","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1056\/NEJMc2301248","volume":"388","author":"G Dusheiko","year":"2023","unstructured":"Dusheiko G, Agarwal K, Maini MK. New approaches to chronic hepatitis B. Reply N Engl J Med. 2023;388(12):1148\u20139. https:\/\/doi.org\/10.1056\/NEJMc2301248.","journal-title":"Reply N Engl J Med"},{"issue":"10042","key":"1969_CR3","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/S0140-6736(16)31144-8","volume":"388","author":"L The","year":"2016","unstructured":"Anon. Towards elimination of viral hepatitis by 2030. Lancet. 2016;388(10042):308. https:\/\/doi.org\/10.1016\/S0140-6736(16)31144-8.","journal-title":"Lancet"},{"issue":"2","key":"1969_CR4","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"P Lampertico","year":"2017","unstructured":"Lampertico P, Agarwal K, Berg T, et al. EASL 2017 Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021.","journal-title":"J Hepatol"},{"issue":"3","key":"1969_CR5","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/hep.27894","volume":"62","author":"GL Wong","year":"2015","unstructured":"Wong GL, Tse Y, Wong VW, et al. Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: a cohort study of 53,500 subjects. Hepatology. 2015;62(3):684\u201393. https:\/\/doi.org\/10.1002\/hep.27894.","journal-title":"Hepatology"},{"key":"1969_CR6","doi-asserted-by":"publisher","first-page":"iv45","DOI":"10.1093\/ndt\/gfu217","volume":"29","author":"CA Wagner","year":"2014","unstructured":"Wagner CA, Rubio-Aliaga I, Biber J, et al. Genetic diseases of renal phosphate handling. Nephrol Dial Transplant. 2014;29:iv45-54. https:\/\/doi.org\/10.1093\/ndt\/gfu217.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"1969_CR7","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1002\/hep.23346","volume":"50","author":"CM Lange","year":"2009","unstructured":"Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology. 2009;50(6):2001\u20136. https:\/\/doi.org\/10.1002\/hep.23346.","journal-title":"Hepatology"},{"issue":"4","key":"1969_CR8","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","volume":"68","author":"K Agarwal","year":"2018","unstructured":"Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide versus Tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68(4):672\u201381. https:\/\/doi.org\/10.1016\/j.jhep.2017.11.039.","journal-title":"J Hepatol"},{"issue":"3","key":"1969_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00228-023-03616-y","volume":"80","author":"K Tong","year":"2024","unstructured":"Tong K, Chen M, Wang D, et al. Effects of first-line nucleot(s)ide analogues on lipid profiles in patients with chronic hepatitis B: a network meta-analysis. Eur J Clin Pharmacol. 2024;80(3):335\u201354. https:\/\/doi.org\/10.1007\/s00228-023-03616-y.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"1969_CR10","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s11096-023-01678-7","volume":"46","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Jiang H, Xue L, et al. Exploring the safety profile of tremelimumab: an analysis of the FDA adverse event reporting system. Int J Clin Pharm. 2024;46(2):480\u20137. https:\/\/doi.org\/10.1007\/s11096-023-01678-7.","journal-title":"Int J Clin Pharm"},{"issue":"9","key":"1969_CR11","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3760\/cma.j.cn501113-20200117-00020","volume":"29","author":"X Liu","year":"2021","unstructured":"Liu X, Chen L, Zhao L. Study on mining of signals of adverse drug reactions of entecavir and tenofovir disoproxil based on the US FAERS database. Zhonghua Gan Zang Bing Za Zhi. 2021;29(9):830\u20136. https:\/\/doi.org\/10.3760\/cma.j.cn501113-20200117-00020.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"1969_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2391496","author":"M Zhu","year":"2024","unstructured":"Zhu M, Jia L, Wang Y, et al. Comparative evaluation of adverse drug reactions for tenofovir alafenamide and tenofovir disoproxil fumarate using the FAERS database: a disproportionality analysis. Expert Opin Drug Saf. 2024. https:\/\/doi.org\/10.1080\/14740338.2024.2391496.","journal-title":"Expert Opin Drug Saf"},{"key":"1969_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.772768","volume":"12","author":"R Yang","year":"2021","unstructured":"Yang R, Yin N, Zhao Y, et al. Adverse events during pregnancy associated with entecavir and adefovir: new insights from a real-world analysis of cases reported to FDA adverse event reporting system. Front Pharmacol. 2021;12: 772768. https:\/\/doi.org\/10.3389\/fphar.2021.772768.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1969_CR14","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s11096-023-01556-2","volume":"45","author":"M Cao","year":"2023","unstructured":"Cao M, Pan C, Tian Y, et al. Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis. Int J Clin Pharm. 2023;45(3):689\u201397. https:\/\/doi.org\/10.1007\/s11096-023-01556-2.","journal-title":"Int J Clin Pharm"},{"issue":"10","key":"1969_CR15","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa051287","volume":"354","author":"C Lai","year":"2006","unstructured":"Lai C, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354(10):1011\u201320. https:\/\/doi.org\/10.1056\/NEJMoa051287.","journal-title":"N Engl J Med"},{"issue":"1","key":"1969_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/jvh.12613","volume":"24","author":"Y Liu","year":"2017","unstructured":"Liu Y, Corsa AC, Buti M, et al. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8\u00a0years of treatment. J Viral Hepat. 2017;24(1):68\u201374. https:\/\/doi.org\/10.1111\/jvh.12613.","journal-title":"J Viral Hepat"},{"issue":"6","key":"1969_CR17","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.14218\/JCTH.2023.00320","volume":"11","author":"H You","year":"2023","unstructured":"You H, Wang F, Li T, et al. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). J Clin Transl Hepatol. 2023;11(6):1425\u201342. https:\/\/doi.org\/10.14218\/JCTH.2023.00320.","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"1969_CR18","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1080\/22221751.2019.1584018","volume":"8","author":"Y Liu","year":"2019","unstructured":"Liu Y, Zhou Y, Li X, et al. Hepatitis B virus mutation pattern rtl180m+a181c+m204v may contribute to entecavir resistance in clinical practice. Emerg Microbes Infect. 2019;8(1):354\u201365. https:\/\/doi.org\/10.1080\/22221751.2019.1584018.","journal-title":"Emerg Microbes Infect"},{"issue":"4","key":"1969_CR19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/hepr.13618","volume":"51","author":"F Suzuki","year":"2021","unstructured":"Suzuki F, Sezaki H, Hosaka T, et al. Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir. Hepatol Res. 2021;51(4):503\u20138. https:\/\/doi.org\/10.1111\/hepr.13618.","journal-title":"Hepatol Res"},{"issue":"5","key":"1969_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101119","volume":"28","author":"F Da Wang","year":"2023","unstructured":"Da Wang F, Zhou J, Li L, et al. Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir. Ann Hepatol. 2023;28(5): 101119. https:\/\/doi.org\/10.1016\/j.aohep.2023.101119.","journal-title":"Ann Hepatol"},{"issue":"12","key":"1969_CR21","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1097\/CM9.0000000000003171","volume":"137","author":"Y Xu","year":"2024","unstructured":"Xu Y, Xia C, Li H, et al. Survey of hepatitis B virus infection for liver cancer screening in China: a population-based, cross-sectional study. Chin Med J (Engl). 2024;137(12):1414\u201320. https:\/\/doi.org\/10.1097\/CM9.0000000000003171.","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"1969_CR22","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.cgh.2023.09.002","volume":"22","author":"A Chau","year":"2024","unstructured":"Chau A, Yeh M, Tsai P, et al. Sex differences in treatment response to nucleos(t)ide therapy in chronic hepatitis B: a multicenter longitudinal study. Clin Gastroenterol Hepatol. 2024;22(3):572\u201380. https:\/\/doi.org\/10.1016\/j.cgh.2023.09.002.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"1969_CR23","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.2741\/4541","volume":"22","author":"SR Lee","year":"2017","unstructured":"Lee SR, Kim N, Noh YH, et al. Mitochondrial DNA, mitochondrial dysfunction, and cardiac manifestations. Front Biosci (Landmark Ed). 2017;22(7):1177\u201394. https:\/\/doi.org\/10.2741\/4541.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"1969_CR24","doi-asserted-by":"publisher","first-page":"46344","DOI":"10.1038\/srep46344","volume":"7","author":"X Zhao","year":"2017","unstructured":"Zhao X, Sun K, Lan Z, et al. Tenofovir and adefovir down-regulate mitochondrial chaperone TRAP1 and succinate dehydrogenase subunit b to metabolically reprogram glucose metabolism and induce nephrotoxicity. Sci Rep. 2017;7:46344. https:\/\/doi.org\/10.1038\/srep46344.","journal-title":"Sci Rep"},{"issue":"2\u20133","key":"1969_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.bbabio.2004.09.005","volume":"1659","author":"AM Schaefer","year":"2004","unstructured":"Schaefer AM, Taylor RW, Turnbull DM, et al. The epidemiology of mitochondrial disorders\u2013past, present and future. Biochim Biophys Acta. 2004;1659(2\u20133):115\u201320. https:\/\/doi.org\/10.1016\/j.bbabio.2004.09.005.","journal-title":"Biochim Biophys Acta"},{"key":"1969_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/nu14071483","author":"P Pludowski","year":"2022","unstructured":"Pludowski P, Takacs I, Boyanov M, et al. Clinical practice in the prevention, diagnosis and treatment of vitamin D deficiency: a central and eastern European expert consensus statement. Nutrients. 2022. https:\/\/doi.org\/10.3390\/nu14071483.","journal-title":"Nutrients"},{"issue":"9865","key":"1969_CR27","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"381","author":"P Marcellin","year":"2013","unstructured":"Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(12)61425-1.","journal-title":"Lancet"},{"issue":"48","key":"1969_CR28","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40618-024-02458-4","volume":"2024","author":"I Chiodini","year":"2025","unstructured":"Chiodini I, d\u2019Angela D, Falchetti A, et al. Areas of uncertainty on the diagnosis, treatment, and follow-up of hypophosphatemia in adults: an Italian Delphi consensus. J Endocrinol Invest. 2025;2024(48):257\u201367. https:\/\/doi.org\/10.1007\/s40618-024-02458-4.","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"1969_CR29","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2021.12.016","volume":"185","author":"A Sakers","year":"2022","unstructured":"Sakers A, De Siqueira MK, Seale P, et al. Adipose-tissue plasticity in health and disease. Cell. 2022;185(3):419\u201346. https:\/\/doi.org\/10.1016\/j.cell.2021.12.016.","journal-title":"Cell"},{"issue":"2","key":"1969_CR30","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.cgh.2021.04.045","volume":"20","author":"KS Byun","year":"2022","unstructured":"Byun KS, Choi J, Kim J, et al. Tenofovir alafenamide for drug-resistant hepatitis B: a randomized trial for switching from tenofovir disoproxil fumarate. Clin Gastroenterol Hepatol. 2022;20(2):427\u201337. https:\/\/doi.org\/10.1016\/j.cgh.2021.04.045.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1969_CR31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3350\/cmh.2023.0328","volume":"30","author":"H Hong","year":"2024","unstructured":"Hong H, Choi W, Lee D, et al. Cardiovascular risk in chronic hepatitis b patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide. Clin Mol Hepatol. 2024;30(1):49\u201363. https:\/\/doi.org\/10.3350\/cmh.2023.0328.","journal-title":"Clin Mol Hepatol"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01969-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-01969-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01969-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T08:31:04Z","timestamp":1757665864000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-01969-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1969"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-01969-1","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Because FAERS is a publicly available and anonymized database, this study did not require ethical approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}